Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has maintained an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) but lowered the price target from $95 to $90.
October 10, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Ultragenyx Pharmaceutical but lowered the price target from $95 to $90.
The news is directly about Ultragenyx Pharmaceutical. While the Overweight rating is maintained, which is positive, the lowering of the price target from $95 to $90 might have a neutral to slightly negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100